Nuclear Imaging

Molecular imaging, also called nuclear imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. 

The Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab (brand name Aduhelm) and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating Alzheimer’s disease.
News | PET Imaging
CMS Finalizes Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

April 8, 2022 — The Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab ...

Time April 08, 2022
arrow
RaySearch Laboratories AB announces that Mevion China has placed an order for RayStation which Mevion China has sold together with Mevion’s HYPERSCAN proton therapy system to Tongji Hospital in Wuhan in China
News | Treatment Planning
Tongji Hospital Selects RayStation

April 7, 2022 — RaySearch Laboratories AB announces that Mevion China has placed an order for RayStation which Mevion ...

Time April 07, 2022
arrow
Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Centralized Application for Marketing Authorization to the European Medicine Agency (EMA) for Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent (GBCA).
News | Contrast Media
Gadopiclenol Marketing Authorization Dossier Submissions Accepted for Review by EMA and FDA

April 6, 2022 — Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products ...

Time April 06, 2022
arrow
GE Healthcare announced the first patient dosed in the Phase III clinical trial for a Positron Emission Tomography (PET) radiopharmaceutical imaging agent which aims to assist in the evaluation of adult patients with suspected Parkinsonian syndromes, support research and improve patient care. 
News | PET Imaging
GE Healthcare Announces First Patient Dosed in Phase III Clinical Trial for New Dopamine Transporter Imaging Radiopharmaceutical

March 29, 2022 — GE Healthcare announced the first patient dosed in the Phase III clinical trial for a Positron Emission ...

Time March 29, 2022
arrow
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports Advanced Accelerator Applications, a Novartis company, as a long-term supplier for the medical radioisotope component of the newly U.S. Food and Drug Administration (FDA) approved radiotherapeutic, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treat
News | Prostate Cancer
ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer

March 28, 2022 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports ...

Time March 28, 2022
arrow
With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC)—the Society of Nuclear Medicine and Molecular Imaging (SNMMI) celebrates one of the greatest success stories in nuclear medicine history.
News | Prostate Cancer
SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment

March 23, 2022 — With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical ...

Time March 23, 2022
arrow
F-18 FDG PET in COVID-19–related CNS disorders: Principal components analysis of spatial covariance pattern (first row) and statistical parametric mapping analysis of metabolic group differences (second to fifth rows) in patients with COVID-19–related encephalopathy, patients with post-COVID-19 syndrome, and patients with post-COVID-19 syndrome and hyposmia compared to healthy controls (n=13). Image Created by PT Meyer, S Hellwig, G Blazhenets and JA Hosp, Medical Center – University of Freiburg, Germany.
News | Coronavirus (COVID-19)
Molecular Imaging Uncovers Effects of COVID-19 on the Brain

March 23, 2022 — A significant number of COVID-19 neurological complications— such as fatigue, headache, and cognitive ...

Time March 23, 2022
arrow
Studies show that radiologists suffer from burnout more than most other medical professionals, in part due to long hours, complex cases and inefficiencies in radiology workflows.
Feature | Information Technology | By Christian Bazinet
Working Smarter, Not Harder, in Radiology Imaging

Studies show that radiologists suffer from burnout more than most other medical professionals, in part due to long hours ...

Time March 21, 2022
arrow
On March 17, NRG restarted the reactor in Petten, The Netherlands. At around 11 a.m., the capacity of 45 MW has been reached.
News | Nuclear Imaging
NRG High Flux Reactor Back in Full Operation

March 18, 2022 — On March 17, NRG restarted the reactor in Petten, The Netherlands. At around 11 a.m., the capacity of ...

Time March 18, 2022
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named Stanford Health Care and the Dana-Farber Brigham Cancer Center as its first two designated Radiopharmaceutical Therapy Centers of Excellence.
News | SNMMI
SNMMI designates first Radiopharmaceutical Therapy Centers of Excellence

March 16, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named Stanford Health Care and the ...

Time March 16, 2022
arrow
Convergent will use NorthStar’s Ac-225 to radiolabel its lead asset, CONV01-α, a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody, currently being investigated as a potential ground-breaking treatment for prostate cancer.
News | Prostate Cancer
NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

March 11, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time March 11, 2022
arrow
NeuroLogica’s OmniTom Elite has received 510(k) clearance for the addition of Photon Counting Detector (PCD) technology
News | SPECT-CT
NeuroLogica Announces FDA 510(k) Clearance for Photon Counting Computed Tomography Using OmniTom Elite

March 11, 2022 — The world of medical imaging is no longer just black and white. NeuroLogica Corp., a subsidiary of ...

Time March 11, 2022
arrow
Sponsored Content | Sponsored Content | Videos | Computed Tomography (CT)
Talking Trends with Philips: Advancements in CT Technology

At RSNA 2021, Philips highlighted the launch of two new innovative CT systems – the multi-energy Spectral CT 7500 and ...

Time March 09, 2022
arrow
The American College of Radiology (#ACR) joins all Americans in calling for an immediate end to fighting in #Ukraine enabling medical providers to safely care for the sick and injured and humanitarian organizations to supply necessary aid. #UkraineUnderAttack
News | Nuclear Imaging
ACR Statement on Ukraine Invasion and Resulting Humanitarian Crisis

March 4, 2022 — The American College of Radiology (ACR) joins all Americans in calling for an immediate end to fighting ...

Time March 04, 2022
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) deplores the recent invasion of Ukraine that has resulted in the death and injury of a large number of innocent men, women, and children—a horrifying contrast to our work to save lives and improve patient care.
News | Nuclear Imaging
Position Statement from SNMMI Regarding Situation in Ukraine

March 3, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) deplores the recent invasion of Ukraine ...

Time March 03, 2022
arrow
Surge in demand for the effective diagnostic system, technological advancements, and increase in the prevalence of diseases have boosted the growth of the global PET-CT scanner device market
News | PET-CT
Global PET-CT Scanner Device Market to Hit $3.20 Billion by 2030

February 23, 2022 — Surge in demand for the effective diagnostic system, technological advancements, and increase in the ...

Time February 23, 2022
arrow
The global diagnostic imaging market is projected to reach $35 billion by 2026 from $26.6 billion in 2020, at a CAGR of 5.7% from 2021 to 2026.
News | Radiology Imaging
Diagnostic Imaging Markets Global Forecast

February 21, 2022 — The global diagnostic imaging market is projected to reach $35 billion by 2026 from $26.6 billion in ...

Time February 21, 2022
arrow
The MARIA research reactor (Poland) has added additional operating days, which has helped to reduce the loss of HFR production capacity.
News | Nuclear Imaging
Update on HFR Reactor Outage – Medical Isotope Supply Returning to Normal

February 18, 2022 — The Nuclear Medicine Europe (NMEu) Emergency Response Team held a call on February 14 on the ...

Time February 18, 2022
arrow
Already used in single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) for adult patients, Rapiscan is now approved for use in stress cardiac magnetic resonance imaging (CMR)
News | SPECT Imaging
GE Healthcare’s Stress Agent Rapiscan Approved for use in Stress Cardiac Magnetic Resonance Imaging

February 18, 2022 — GE Healthcare has announced that it has received approval from the European Medicines Agency (EMA) ...

Time February 18, 2022
arrow
18F-rhPSMA-7.3 PET Photo courtesy of Blue Earth Diagnostics. General use: This 18F-rhPSMA-7.3 PET image shows prostate cancer spread beyond the prostate region. Technical use: This 18F-rhPSMA-7.3 PET image shows detection of recurrent prostate cancer in several retroperitoneal lymph nodes, as indicated by the green arrows.
News | Prostate Cancer
Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of 18F-rhPSMA-7.3

February 18, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time February 18, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now